Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease.

Manchia M, Squassina A, Pisanu C, Congiu D, Garzilli M, Guiso B, Suprani F, Paribello P, Pulcinelli V, Iaselli MN, Pinna F, Valtorta F, Carpiniello B, Comai S.

Int J Bipolar Disord. 2019 Dec 9;7(1):27. doi: 10.1186/s40345-019-0163-y.

2.

Biomarkers in aggression.

Manchia M, Comai S, Pinna M, Pinna F, Fanos V, Denovan-Wright E, Carpiniello B.

Adv Clin Chem. 2019;93:169-237. doi: 10.1016/bs.acc.2019.07.004. Epub 2019 Sep 11. Review.

PMID:
31655730
3.

Grey and white matter structure associates with the activation of the tryptophan to kynurenine pathway in bipolar disorder.

Poletti S, Melloni E, Aggio V, Colombo C, Valtorta F, Benedetti F, Comai S.

J Affect Disord. 2019 Dec 1;259:404-412. doi: 10.1016/j.jad.2019.08.034. Epub 2019 Aug 19.

PMID:
31610997
4.

Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle.

López-Canul M, Min SH, Posa L, De Gregorio D, Bedini A, Spadoni G, Gobbi G, Comai S.

Int J Mol Sci. 2019 May 17;20(10). pii: E2452. doi: 10.3390/ijms20102452.

5.

Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications, and perspectives.

Comai S, Lopez-Canul M, De Gregorio D, Posner A, Ettaoussi M, Guarnieri FC, Gobbi G.

Pharmacol Res. 2019 Jun;144:343-356. doi: 10.1016/j.phrs.2019.04.015. Epub 2019 Apr 25. Review.

PMID:
31029764
6.

Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep.

Gobbi G, Comai S.

Front Endocrinol (Lausanne). 2019 Mar 1;10:87. doi: 10.3389/fendo.2019.00087. eCollection 2019. Review.

7.

Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep.

Gobbi G, Comai S.

J Pineal Res. 2019 Apr;66(3):e12544. doi: 10.1111/jpi.12544. Epub 2019 Jan 21.

PMID:
30586215
8.

Trace elements among a sample of prisoners with mental and personality disorders and aggression: correlation with impulsivity and ADHD indices.

Comai S, Bertazzo A, Vachon J, Daigle M, Toupin J, Côté G, Gobbi G.

J Trace Elem Med Biol. 2019 Jan;51:123-129. doi: 10.1016/j.jtemb.2018.10.008. Epub 2018 Oct 5.

PMID:
30466921
10.

Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.

De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G.

Pain. 2019 Jan;160(1):136-150. doi: 10.1097/j.pain.0000000000001386.

11.

Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.

Aguilar-Valles A, Haji N, De Gregorio D, Matta-Camacho E, Eslamizade MJ, Popic J, Sharma V, Cao R, Rummel C, Tanti A, Wiebe S, Nuñez N, Comai S, Nadon R, Luheshi G, Mechawar N, Turecki G, Lacaille JC, Gobbi G, Sonenberg N.

Nat Commun. 2018 Jun 25;9(1):2459. doi: 10.1038/s41467-018-04883-5.

12.

High frequency stimulation of the anterior vermis modulates behavioural response to chronic stress: involvement of the prefrontal cortex and dorsal raphe?

Bambico FR, Comai S, Diwan M, Hasan SMN, Conway JD, Darvish-Ghane S, Hamani C, Gobbi G, Nobrega JN.

Neurobiol Dis. 2018 Aug;116:166-178. doi: 10.1016/j.nbd.2018.03.011. Epub 2018 May 2.

PMID:
29727711
13.

Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide.

Messaoud A, Mensi R, Douki W, Neffati F, Najjar MF, Gobbi G, Valtorta F, Gaha L, Comai S.

World J Biol Psychiatry. 2019 Nov;20(9):703-711. doi: 10.1080/15622975.2018.1468031. Epub 2018 May 23.

PMID:
29683396
14.

Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study.

Nuñez NA, Comai S, Dumitrescu E, Ghabrash MF, Tabaka J, Saint-Laurent M, Vida S, Kolivakis T, Fielding A, Low N, Cervantes P, Booij L, Gobbi G.

BMC Psychiatry. 2018 Mar 16;18(1):68. doi: 10.1186/s12888-018-1641-y.

15.

Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.

Atkin T, Comai S, Gobbi G.

Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Review.

PMID:
29487083
16.

Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.

Gobbi G, Ghabrash MF, Nuñez N, Tabaka J, Di Sante J, Saint-Laurent M, Vida S, Kolivakis T, Low N, Cervantes P, Booij L, Comai S.

Int Clin Psychopharmacol. 2018 Jan;33(1):34-43. doi: 10.1097/YIC.0000000000000196.

PMID:
28906325
17.

Serotonin Dysfunction, Aggressive Behavior, and Mental Illness: Exploring the Link Using a Dimensional Approach.

Manchia M, Carpiniello B, Valtorta F, Comai S.

ACS Chem Neurosci. 2017 May 17;8(5):961-972. doi: 10.1021/acschemneuro.6b00427. Epub 2017 Apr 10. Review.

PMID:
28378993
18.

Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain.

Posa L, De Gregorio D, Gobbi G, Comai S.

Curr Med Chem. 2018;25(32):3866-3882. doi: 10.2174/0929867324666170209104926. Review.

PMID:
28183259
19.

d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.

De Gregorio D, Comai S, Posa L, Gobbi G.

Int J Mol Sci. 2016 Nov 23;17(11). pii: E1953. Review.

20.

The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors.

De Gregorio D, Posa L, Ochoa-Sanchez R, McLaughlin R, Maione S, Comai S, Gobbi G.

Pharmacol Res. 2016 Nov;113(Pt A):81-91. doi: 10.1016/j.phrs.2016.08.022. Epub 2016 Aug 17.

PMID:
27544651

Supplemental Content

Loading ...
Support Center